tetano
Editor, Senior Moderator
Vaccines (Basel)
. 2022 Sep 2;10(9):1456.
doi: 10.3390/vaccines10091456.
Relative Vaccine Effectiveness of Adjuvanted Trivalent Influenza Vaccine over Three Consecutive Influenza Seasons in the United States
Constantina Boikos[SUP] 1 [/SUP], Ian McGovern[SUP] 2 [/SUP], Justin R Ortiz[SUP] 3 [/SUP], Joan Puig-Barberà[SUP] 4 [/SUP], Eve Versage[SUP] 2 [/SUP], Mendel Haag[SUP] 5 [/SUP]
Affiliations
Abstract
Traditional influenza vaccines may be less immunogenic in adults ≥65 years of age due to immunosenescence. Two influenza vaccines-MF59®-adjuvanted trivalent inactivated influenza vaccine (aIIV3) and high-dose influenza vaccine (HD-IIV3)-were developed to overcome this problem. We summarize estimates of the relative vaccine effectiveness (rVE) of aIIV3 vs. HD-IIV3 and aIIV3 vs. standard, egg-based quadrivalent influenza vaccines (IIV4e) during the 2017-2018, 2018-2019, and 2019-2020 US influenza seasons using the same underlying electronic medical record and linked claims dataset for all three seasons. The primary outcome was influenza-related medical encounters (IRMEs), defined by diagnostic codes specific to influenza (ICD J09*-J11*). rVE was estimated using propensity score methods adjusting for demographics and health status. rVE estimates demonstrated consistent benefit for aIIV3 over IIV4e in the overall and at-risk populations. Relative to HD-IIV3, aIIV3 provided improved benefit in the overall study population and comparable benefit in the at-risk population across each season.
Keywords: immunosenescence; influenza; influenza vaccines; relative vaccine effectiveness.
. 2022 Sep 2;10(9):1456.
doi: 10.3390/vaccines10091456.
Relative Vaccine Effectiveness of Adjuvanted Trivalent Influenza Vaccine over Three Consecutive Influenza Seasons in the United States
Constantina Boikos[SUP] 1 [/SUP], Ian McGovern[SUP] 2 [/SUP], Justin R Ortiz[SUP] 3 [/SUP], Joan Puig-Barberà[SUP] 4 [/SUP], Eve Versage[SUP] 2 [/SUP], Mendel Haag[SUP] 5 [/SUP]
Affiliations
- PMID: 36146534
- DOI: 10.3390/vaccines10091456
Abstract
Traditional influenza vaccines may be less immunogenic in adults ≥65 years of age due to immunosenescence. Two influenza vaccines-MF59®-adjuvanted trivalent inactivated influenza vaccine (aIIV3) and high-dose influenza vaccine (HD-IIV3)-were developed to overcome this problem. We summarize estimates of the relative vaccine effectiveness (rVE) of aIIV3 vs. HD-IIV3 and aIIV3 vs. standard, egg-based quadrivalent influenza vaccines (IIV4e) during the 2017-2018, 2018-2019, and 2019-2020 US influenza seasons using the same underlying electronic medical record and linked claims dataset for all three seasons. The primary outcome was influenza-related medical encounters (IRMEs), defined by diagnostic codes specific to influenza (ICD J09*-J11*). rVE was estimated using propensity score methods adjusting for demographics and health status. rVE estimates demonstrated consistent benefit for aIIV3 over IIV4e in the overall and at-risk populations. Relative to HD-IIV3, aIIV3 provided improved benefit in the overall study population and comparable benefit in the at-risk population across each season.
Keywords: immunosenescence; influenza; influenza vaccines; relative vaccine effectiveness.